Characteristics and survival of HIV-infected patients not screened for hepatitis C virus infection in a hospital-based cohort

被引:0
作者
Benet, T.
D'Oliveira, A., Jr.
Voirin, N.
Livrozet, J.-M.
Cotte, L.
Peyramond, D.
Chidiac, C.
Touraine, J. -L.
Fabry, J.
Trepo, C.
Allard, R.
Vanhems, P.
机构
[1] Univ Lyon 1, Lab Epidemiol Sante Publ, UMR 5558, F-69365 Lyon, France
[2] Hop Edouard Herriot, Hospices Civils, Dept Hyg Epidemiol Prevent, Lyon, France
[3] Hop Edouard Herriot, Serv Immunol Clin, Lyon, France
[4] Serv Hepatogastroenterol, Lyon, France
[5] INSERM, U271, Hotel Dieu, Hospices Civils Lyon, Lyon, France
[6] Hop Croix Rousse, Serv Malad Infect & Trop, Hospices Civils Lyon, Lyon, France
[7] McGill Univ, Dept Publ Hlth, Montreal, PQ, Canada
关键词
epidemiology; hepatitis C virus; human immunodeficiency virus; missing data; survival;
D O I
10.1111/j.1365-2893.2007.00863.x
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
The rate of human immunodeficiency virus (HIV) disease progression or death of individuals coinfected with hepatitis C virus (HCV) is conflicting. The complete-case analysis systematically used, excludes patients unscreened for HCV. Our objective was to assess if rate of survival differed between HIV-infected patients screened and unscreened for HCV in a hospital-based prospective cohort study. Patients were enrolled in the Lyon section of the French Hospital Database on HIV between 1 July 1992 and 31 May 2005. A multivariate Cox regression model was used to analyse the association of HCV screening with survival. Of 3244 patients, 299 (9.2%) were not screened for HCV. The populations screened and unscreened differed by the proportion of acquired immune deficiency syndrome at baseline, presumed route of infection, CD4 cell count category at baseline, mean duration of follow-up, mean number of visits per year, type of antiretroviral therapy and survival. The rate of progression to death was higher for non-HCV-screened vs HCV-screened patients: the incidence rate among HCV-screened patients was 22.9/1000 patient-years; the incidence rate among HCV-unscreened patients was 52.4/1000 patient-years. The adjusted hazards ratio of death was 2.48 [95% confidence interval (1.83-3.35); P < 0.001] for patients with unknown HCV status compared with others. In conclusion, unscreened or unknown HCV status was associated with an increased risk of death in our hospital cohort. Important prognostic factors are related to, or confounded by the practice of HCV screening.
引用
收藏
页码:730 / 735
页数:6
相关论文
共 21 条
[1]   Primary care guidelines for the management of persons infected with human immunodeficiency virus: Recommendations of the HIV Medicine Association of the Infectious Diseases Society of America [J].
Aberg, JA ;
Gallant, JE ;
Anderson, J ;
Oleske, JM ;
Libman, H ;
Currier, JS ;
Stone, VE ;
Kaplan, JE .
CLINICAL INFECTIOUS DISEASES, 2004, 39 (05) :609-629
[2]   Hepatitis C virus coinfection increases mortality in HIV-infected patients in the highly active antiretroviral therapy era: Data from the HIV Atlanta VA Cohort Study [J].
Anderson, KB ;
Guest, JL ;
Rimland, D .
CLINICAL INFECTIOUS DISEASES, 2004, 39 (10) :1507-1513
[3]  
Backus LI, 2005, JAIDS-J ACQ IMM DEF, V39, P613
[4]   Survival in patients with HIV infection and viral hepatitis B or C: a cohort study [J].
Bonacini, M ;
Louie, S ;
Bzowej, N ;
Wohl, AR .
AIDS, 2004, 18 (15) :2039-2045
[5]   The prevalence of hepatitis B and C in HIV-positive Greek patients: Relationship to survival of deceased AIDS patients [J].
Dimitrakopoulos, A ;
Takou, A ;
Haida, A ;
Molangeli, S ;
Gialeraki, A ;
Kordossis, T .
JOURNAL OF INFECTION, 2000, 40 (02) :127-131
[6]   A critical look at methods for handling missing covariates in epidemiologic regression analyses [J].
Greenland, S ;
Finkle, WD .
AMERICAN JOURNAL OF EPIDEMIOLOGY, 1995, 142 (12) :1255-1264
[7]   Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: the Swiss HIV Cohort Study [J].
Greub, G ;
Ledergerber, B ;
Battegay, M ;
Grob, P ;
Perrin, L ;
Furrer, H ;
Burgisser, P ;
Erb, P ;
Boggian, K ;
Piffaretti, JC ;
Hirschel, B ;
Janin, P ;
Francioli, P ;
Flepp, M ;
Telenti, A .
LANCET, 2000, 356 (9244) :1800-1805
[8]   An example of nonrandom missing data for hepatitis C virus status in a prognostic study among HIV-infected patients [J].
Lewden, C ;
Jacqmin-Gadda, H ;
Vildé, JL ;
Bricaire, F ;
Waldner-Combernoux, A ;
May, T ;
Cuzin, L ;
Lang, JM ;
Leport, C ;
Chêne, G .
HIV CLINICAL TRIALS, 2004, 5 (04) :224-231
[9]   Impact of hepatitis C infection on long-term mortality of injecting drug users from 1990 to 2002:: differences before and after HAART [J].
Lumbreras, B ;
Jarrín, I ;
del Amo, J ;
Pérez-Hoyos, S ;
Muga, R ;
García-De la Hera, M ;
Ferreros, I ;
Sanvisens, A ;
Hurtado, I ;
Hernández-Aguado, I .
AIDS, 2006, 20 (01) :111-116
[10]   Characteristics and survival of AIDS patients with hepatitis C: the Brazilian National Cohort of 1995-1996 [J].
Marins, JRP ;
Barros, MBD ;
Machado, H ;
Chen, S ;
Jamal, LF ;
Hearst, N .
AIDS, 2005, 19 :S27-S30